| Literature DB >> 35855984 |
Ruth Edwige Kemadjou Dibacto1,2, Bruno Dupon Akamba Ambamba1, Fils Armand Ella1, Christine Fernande Biyegue Nyangono3, Jules Vidal Kamga Nanhah1, Martin Fonkoua1, Réné Samuel Minka1, Judith Laure Ngondi1.
Abstract
Neurodegenerative disease such as Alzheimer's disease, are progressive disorders which has been linked to oxidative imbalance and associated perturbations characterised by loss of memory, cognition and cholinergic deficit. To date, cholinesterase inhibition and neuroprotection are the two major strategies in drug development. Xylopia parviflora (Annonacea family) is a spice consumed in Cameroon and has been used in traditional medicine to treat various pains. In this study, X. parviflora was evaluated on behavioural studies, ion homeostasis, cholinesterase inhibitory and antioxidant activities. Rats were exposed to aluminium chloride (75 mg/kg) during 60 days, and were treated with the extract of X. parviflora (150 and 300 mg/kg BW) and two drugs references (Donepezil and Curcumin). Behavioural parameters were assessed using the Morris-Maze test and the Open Field, followed by biochemical investigations, namely, cholinesterase enzyme activity (AChE and BChE), oxidative stress (NO, MDA, GSH level, SOD and Catalase activities) and ion homeostasis (Mg2+ and Ca2+ levels). AlCl3 administration shows a decrease in learning and memory improvement during behavioural studies, significant alteration of the central cholinergic system characterised by an increase in AChE and BChE activities to 2.72 ± 0.002 mol/min/g and 5.74 ± 0.12 mol/min/g respectively, disturbance of ion homeostasis with an increase in Ca2+ level (25.68 ± 3.78 μmol/mg protein) and a decrease in Mg2+ level (15.97 ± 2.05 μmol/mg protein) and an increase in oxidative stress compared to the positive control group. Treatment with the different doses of X. parviflora increased memory and improved locomotion, improved cholinesterase activities, ion homeostasis and stabilized brain oxidative stress levels. The study suggests that X. parviflora could potentially be used for the management of some biochemical alterations associated with Alzheimer's disease. It could even be a good alternative to chemical drugs for neurotoxicity and memory enhancement.Entities:
Keywords: Alzheimer’s disease; Antioxidant stress marker; Cholinesterase; Cognitive function; Neurotoxicity; Xylopia parviflora
Year: 2022 PMID: 35855984 PMCID: PMC9287802 DOI: 10.1016/j.heliyon.2022.e09896
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Experimental design and drug doses in different groups of rats.
| Groups | Name of groups | Compounds and drugs administered |
|---|---|---|
| NC | Normal Control | Distilled water |
| PC | Positive Control | AlCl3 (75 mg/kg BW/day) + Distilled water |
| XP 150 | Test group 1 | AlCl3 (75 mg/kg BW/day) + Combine filtrate of |
| XP 300 | Test group 2 | AlCl3 (75 mg/kg BW/day) + Combine filtrate of |
| Donep5 | Standard treatment cholinesterase | AlCl3 (75 mg/kg bw/day) + Donepezil (5 mg/kg BW/day) |
| Cur | Standard treatment antioxidant | AlCl3 (75 mg/kg BW/day) + Curcumin (100 mg/kg BW/day) |
Figure 1Effects of . Animals were treated without or with AlCl3 (75 mg/kg/BW per os), or cotreated with AlCl3 (75 mg/kg/BW per os) and extract of Xylopia parviflora (150 and 300 mg/kg/BW/day per os) or reference compounds (Donepezil, 5 mg/kg/BW/day per os) and (Curcumin, 100 mg/kg/PC/day per os) for 60 days. Behavioural parameters (memory impairment) were performed during and at the end of the experimental (A): Effect of extract on number of entries in the target quadrant of the Morris Maze (B): Effect of extract on time spent in the target quadrant of the Morris Maze (C): Effect of extract on latency to enter in the target quadrant of the Morris Maze (D): Effect of extract on distance covered in the target quadrant of the Morris Maze. ap < 0.05 vs positive control (PC).
Figure 2Effects of . Animals were treated without or with AlCl3 (75 mg/kg/BW per os), or cotreated with AlCl3 (75 mg/kg/BW per os) and extract of Xylopia parviflora (150 and 300 mg/kg/BW/day per os) or reference compounds (Donepezil, 5 mg/kg/BW/day per os) and (Curcumin, 100 mg/kg/BW/day per os) for 60 days. Behavioural parameters (locomotion impairment) were performed during and at the end of the experimental (A): Effect of extract on distance covered (B): Effect of extract on number of turnarounds; C: Effect of extract on down time. ap < 0.05 vs positive control (PC).
Effect of Xylopia parviflora on brain atrophy and cholinesterase activities in female rats treated with aluminum chloride for 60 days.
| Groups | RBW | AChE (mol/min/g) | BuChE (mol/min/g) |
|---|---|---|---|
| NC | 0.0081 ± 0.0002 | 1.30 ± 0.03a | 4.31 ± 0.02a |
| PC | 0.0079 ± 0.0003 | 2.72 ± 0.02 | 5.74 ± 0.12 |
| XP150 | 0.0082 ± 0.0005 | 1.95 ± 0.01a | 4.58 ± 0.07a |
| XP300 | 0.0081 ± 0.0001 | 1.40 ± 0.03a | 4.48 ± 0.21a |
| Donep5 | 0.0080 ± 0.0001 | 1.25 ± 0.02a | 4.40 ± 0.11a |
| Cur 100 | 0.0080 ± 0.0001 | 1.62 ± 0.03a | 4.75 ± 0.04a |
NC: Normal Control; PC: Positive Control; RBW: Relative brain weight; Donep: Donepezil; Cur: Curcumin. The values are expressed as mean ± sem. ap < 0.05 vs positive control (PC).
Effect of Xylopia parviflora on Mg2+and Ca2+concentrations in the brains of rats.
| Groups | Calcium (μmol/mg protein) | Magnesium (μmol/mg protein) |
|---|---|---|
| NC | 20.84 ± 2.28a | 28.91 ± 1.01a |
| PC | 25.68 ± 3.78 | 15.97 ± 2.05 |
| XP150 | 20.75 ± 3.56a | 25.85 ± 2.02a |
| XP300 | 15.80 ± 3.2b | 30.90 ± 1.15a |
| Donep5 | 14.48 ± 4.24b | 27.89 ± 2.02a |
| Cur 100 | 18.97 ± 3.56a | 23.87 ± 1.01a |
NC: Normal Control; PC: Positive Control; Donep: Donepezil; Cur: Curcumin. The values are expressed as mean ± sem. ap < 0.05; bp < 0.01 vs positive control (PC).
Effect of X. parviflora extract on cerebral antioxidant status in the female rats.
| Groups | NO (mmol/g) | MDA (mmol/g) | Glutathione (mmol/g) | SOD (unit/mg protein) | Catalase (mmol H2O2/mg protein) | Protein (g/dL) |
|---|---|---|---|---|---|---|
| NC | 4.57 ± 0.52a | 60.70 ± 5.10a | 5.16 ± 0.48a | 35.72 ± 5.02a | 290.56 ± 14.34a | 5.96 ± 1.23 |
| PC | 7.52 ± 0.39 | 110.16 ± 8.13 | 2.51 ± 0.20 | 26.86 ± 6.29 | 115.25 ± 10.65 | 5.80 ± 0.55 |
| XP150 | 4.85 ± 0.79a | 70.99 ± 6.11b | 5.20 ± 0.57a | 32.93 ± 4.97a | 274.36 ± 18.78a | 6.12 ± 0.23 |
| XP300 | 4.60 ± 0.49a | 64.87 ± 3.11a | 5.49 ± 0.1a | 36.85 ± 3.21a | 325.00 ± 18.89c | 5.96 ± 0.78 |
| Donep5 | 5.05 ± 0.50a | 85.48 ± 5.14b | 4.6 ± 0.13b | 28.85 ± 3.33 | 251.44 ± 32.55a | 6.29 ± 1.04 |
| Cur 100 | 4.59 ± 0.90a | 60.92 ± 7.19a | 5.67 ± 0.22a | 37.45 ± 4.5a | 423.60 ± 10.14c | 6.04 ± 0.11 |
NC: Negative Control; PC: Positive Control; Donep: Donepezil; Cur: Curcumin; NO: Nitric oxide, MDA: Malondialhyde, SOD: SuperOxide Dismutase. The values are expressed as an average ±standard error on the average. ap < 0.05; bp < 0.01; cp < 0.001 vs positive control (PC).
Effect of X. parviflora extract on ATPases Activities in Brain.
| Groups | Mg2+-ATPase (μmol Pi/h/mg protein) | Ca2+-ATPase (μmol Pi/h/mg protein) | Na+, K+-ATPase (μmol Pi/h/mg protein) |
|---|---|---|---|
| NC | 5.50 ± 0.02a | 2.84 ± 0.01a | 3.80 ± 0.06a |
| PC | 3.70 ± 0.03 | 1.50 ± 0.04 | 2.40 ± 0.03 |
| XP150 | 5.90 ± 0.03a | 2.80 ± 0.01a | 3.50 ± 0.02a |
| XP300 | 6.10 ± 0.023a | 3.08 ± 0.03a | 4.10 ± 0.04a |
| Donep5 | 4.00 ± 0.01a | 3.15 ± 0.05a | 3.90 ± 0.05a |
| Cur 100 | 4.90 ± 0.02a | 2.88 ± 0.01a | 4.15 ± 0.01a |
NC: Normal Control; PC: Positive Control; Donep: Donepezil; Cur: Curcumin. The values are expressed as mean ± sem. ap < 0.05 vs positive control (PC).
Figure 3Microphotographs of Ammon’shorns (X400) of the hippocampus; Hematoxylin-eosin staining. Animals were treated without or with AlCl3 (75 mg/kg/BW per os), or cotreated with AlCl3 (75 mg/kg/BW per os) and extract of Xylopia parviflora (150 and 300 mg/kg/BW/day per os) or reference compounds (Donepezil, 5 mg/kg/BW/day per os) and (Curcumin, 100 mg/kg/BW/day per os) for 60 days. A. Normal control; B. Positive control; C. Donepezil; D. Curcumin; E. Xylopia Parviflora 150; F. Xylopia Parviflora 300.